Compare Citius Pharmaceuticals Inc (CTXR) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Matson Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Matson Inc trades at $210.44 (market cap $6.38B). The key difference: Matson Inc is far larger — about 435.8× Citius Pharmaceuticals Inc's market cap, and Matson Inc pays a 0.72% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MATX | |
|---|---|---|
Market Cap | $14.64M | $6.38B |
Sector | Health | Technology |
52-Week High | $1.82 | $210.95 |
52-Week Low | $0.53 | $88.05 |
Enterprise Value | $10.86M | $6.98B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Matson (MATX) trades at $205.15, up 0.19% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 12.92% net income margin and consistent earnings beats in recent quarters. Recent developments include a dividend increase to $0.38 per share and progress on its LNG-powered vessel construction program, highlighting operational strength and shareholder returns.
The outlook for MATX is positive, supported by niche Pacific shipping routes and resilient earnings. Key opportunities include growth in expedited China service and share repurchases. Risks involve exposure to trade volatility and potential margin pressure from higher costs. Analyst consensus is bullish with 64% buy ratings, but investors should monitor global trade flows and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
